After Another Strong Quarter, WuXi Aims To Become Backbone Of China’s Life Science Industry: China Earnings Roundup (Part 1)
This article was originally published in PharmAsia News
Executive Summary
Despite a macroeconomic slowdown, China’s leading CRO reported another strong quarter due to increasing demand for R&D services from both international and domestic companies.